Experimental combo trial for advanced cancers ends early
NCT ID NCT04000529
First seen Oct 31, 2025 · Last updated May 01, 2026 · Updated 27 times
Summary
This early-stage trial tested a new drug (TNO155) combined with either spartalizumab or ribociclib in 122 adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The main goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Westmead, New South Wales, 2145, Australia
-
Novartis Investigative Site
Brussels, 1200, Belgium
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Cologne, 50937, Germany
-
Novartis Investigative Site
Hong Kong, Hong Kong
-
Novartis Investigative Site
Chuo Ku, Tokyo, 104 0045, Japan
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
Valencia, Valencia, 46010, Spain
Conditions
Explore the condition pages connected to this study.